Clinical Trial Update: Dose-dense Doxorubicin/Cyclophosphamide With Intermittent Low-dose Sunitinib in Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating dose-dense doxorubicin/cyclophosphamide with intermittent low-dose sunitinib in breast cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• Sunitinib (sunitinib)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN